Shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report) dropped 3.1% during mid-day trading on Thursday. The stock traded as low as $0.31 and last traded at $0.31. Approximately 100 shares traded hands during trading, a decline of 100% from the average daily volume of 27,473 shares. The stock had previously closed at $0.32.
Anebulo Pharmaceuticals Trading Up 1.6%
The stock has a 50-day moving average price of $0.33 and a 200 day moving average price of $0.43. The stock has a market capitalization of $12.85 million, a price-to-earnings ratio of -1.66 and a beta of -1.88.
Anebulo Pharmaceuticals Company Profile
Anebulo Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care.
Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings.
Recommended Stories
- Five stocks we like better than Anebulo Pharmaceuticals
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
- Is Synopsys Back from the Dead? EDA Leader Inks Deals With Amazon and OpenAI
- MarketBeat Week in Review – 10/05 – 10/09
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
